Eligibility, Compliance and Persistence of Sequential Therapy with Aromatase Inhibitors following 2–3 Years of Tamoxifen in Endocrine Adjuvant Breast Cancer Therapy

Publisher： Karger

E-ISSN： 1423-0232|81|3-4|151-157

ISSN： 0030-2414

Source： Oncology, Vol.81, Iss.3-4, 2011-10, pp. : 151-157

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Defining the role of aromatase inhibitors in the adjuvant endocrine treatment of early breast cancer

By Buzdar Aman   Chlebowski Rowan   Cuzick Jack   Duffy Sean   Forbes John   Jonat Walter   Ravdin Peter    

Current Medical Research and Opinion, Vol. 22, Iss. 8, 2006-08 ,pp. : 1575-1585

Informa Healthcare

Access to resources Recommend Favorite

Extended adjuvant endocrine therapy of early breast cancer

By Chowdhury Simon   Ellis Paul  

Current Medical Research and Opinion, Vol. 21, Iss. 12, 2005-12 ,pp. : 1985-1995

Informa Healthcare

Access to resources Recommend Favorite

Optimal adjuvant endocrine therapy for early breast cancer

By Stuart-Harris Robin   Davis Alison  

Women's Health, Vol. 6, Iss. 3, 2010-05 ,pp. : 383-398

Future Medicine

Access to resources Recommend Favorite

Prescription Pattern of Aromatase Inhibitors for the Adjuvant Therapy of Breast Cancer in Germany – Results of the Second Survey Among Gynaecologists and Medical Oncologists

By  

Oncology Research and Treatment, Vol. 31, Iss. 1-2, 2008-01 ,pp. : 19-25

Karger

Access to resources Recommend Favorite

Bone mineral density following surgical oophorectomy and tamoxifen adjuvant therapy for breast cancer

By  

CANCER, Vol. 119, Iss. 21, 2013-11 ,pp. : 3746-3752

John Wiley & Sons Inc

Access to resources Recommend Favorite